Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 7
2011 6
2012 15
2013 18
2014 19
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.
Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MKC, Kunz I, Schrauwen-Hinderling VB, Blaak E, Auwerx J, Schrauwen P. Timmers S, et al. Cell Metab. 2011 Nov 2;14(5):612-22. doi: 10.1016/j.cmet.2011.10.002. Cell Metab. 2011. PMID: 22055504 Free PMC article. Clinical Trial.
Here, we treated 11 healthy, obese men with placebo and 150 mg/day resveratrol (resVida) in a randomized double-blind crossover study for 30 days. Resveratrol significantly reduced sleeping and resting metabolic rate. ...
Here, we treated 11 healthy, obese men with placebo and 150 mg/day resveratrol (resVida) in a randomized double-blind crossover study …
Resveratrol levels and all-cause mortality in older community-dwelling adults.
Semba RD, Ferrucci L, Bartali B, Urpí-Sarda M, Zamora-Ros R, Sun K, Cherubini A, Bandinelli S, Andres-Lacueva C. Semba RD, et al. JAMA Intern Med. 2014 Jul;174(7):1077-84. doi: 10.1001/jamainternmed.2014.1582. JAMA Intern Med. 2014. PMID: 24819981 Free PMC article. Clinical Trial.
OBJECTIVE: To determine whether resveratrol levels achieved with diet are associated with inflammation, cancer, cardiovascular disease, and mortality in humans. ...Resveratrol levels were not significantly associated with serum CRP, IL-6, IL-1beta, TNF, prevalent or …
OBJECTIVE: To determine whether resveratrol levels achieved with diet are associated with inflammation, cancer, cardiovascular diseas …
Effect of resveratrol and quercetin supplementation on redox status and inflammation after exercise.
McAnulty LS, Miller LE, Hosick PA, Utter AC, Quindry JC, McAnulty SR. McAnulty LS, et al. Appl Physiol Nutr Metab. 2013 Jul;38(7):760-5. doi: 10.1139/apnm-2012-0455. Epub 2013 Mar 8. Appl Physiol Nutr Metab. 2013. PMID: 23980734 Clinical Trial.
Resveratrol and quercetin function as antioxidants and anti-inflammatories in vitro, but these mechanisms have been minimally examined in combination in exercising humans. ...Fourteen athletes were randomly assigned, in a double-blind crossover design, to a resveratrol …
Resveratrol and quercetin function as antioxidants and anti-inflammatories in vitro, but these mechanisms have been minimally examine …
Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study.
Voduc N, la Porte C, Tessier C, Mallick R, Cameron DW. Voduc N, et al. Appl Physiol Nutr Metab. 2014 Oct;39(10):1183-7. doi: 10.1139/apnm-2013-0547. Epub 2014 Apr 30. Appl Physiol Nutr Metab. 2014. PMID: 25051174 Free article. Clinical Trial.
To assess the effect on exercise capacity and tolerability of resveratrol, 13 healthy, sedentary adult volunteers were enrolled in a randomized crossover study comparing resveratrol and placebo over two 4-week periods, with a 2-week time between periods when subject …
To assess the effect on exercise capacity and tolerability of resveratrol, 13 healthy, sedentary adult volunteers were enrolled in a …
Resveratrol enhances TNF-alpha production in human monocytes upon bacterial stimulation.
Gualdoni GA, Kovarik JJ, Hofer J, Dose F, Pignitter M, Doberer D, Steinberger P, Somoza V, Wolzt M, Zlabinger GJ. Gualdoni GA, et al. Biochim Biophys Acta. 2014 Jan;1840(1):95-105. doi: 10.1016/j.bbagen.2013.09.009. Epub 2013 Sep 12. Biochim Biophys Acta. 2014. PMID: 24035785 Clinical Trial.
BACKGROUND: Resveratrol is a key component of red wine that has been reported to have anti-carcinogenic and anti-aging properties. ...Plasma cytokine levels were measured over 48h after oral application of 5g resveratrol. To verify the in vivo findings, cytokine rel …
BACKGROUND: Resveratrol is a key component of red wine that has been reported to have anti-carcinogenic and anti-aging properties. .. …
Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial.
Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, Villois P, Durazzo M, Cavallo-Perin P, Cassader M. Bo S, et al. Curr Med Chem. 2013;20(10):1323-31. doi: 10.2174/0929867311320100009. Curr Med Chem. 2013. PMID: 23298135 Free article. Clinical Trial.
We evaluated whether resveratrol has beneficial effects on markers of inflammation and oxidative stress in smokers. METHODS AND RESULTS: A randomized, double- blind, cross-over trial was performed in 50 healthy adult smokers: 25 were randomly allocated to "resveratrol …
We evaluated whether resveratrol has beneficial effects on markers of inflammation and oxidative stress in smokers. METHODS AND RESUL …
Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study.
Anton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C, Manini TM. Anton SD, et al. Exp Gerontol. 2014 Sep;57:181-7. doi: 10.1016/j.exger.2014.05.015. Epub 2014 May 24. Exp Gerontol. 2014. PMID: 24866496 Free PMC article. Clinical Trial.
Participants were randomized into one of three treatment groups: (1) placebo, (2) moderate dose resveratrol (300mg/day), and (3) high dose resveratrol (1000mg/day). Both resveratrol and placebo were orally ingested in capsule form twice daily for 90days. ...
Participants were randomized into one of three treatment groups: (1) placebo, (2) moderate dose resveratrol (300mg/day), and (3) high …
Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ. Chachay VS, et al. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2092-103.e1-6. doi: 10.1016/j.cgh.2014.02.024. Epub 2014 Feb 25. Clin Gastroenterol Hepatol. 2014. PMID: 24582567 Clinical Trial.
Resveratrol did not significantly alter transcription of NQO1, PTP1B, IL6, or HO1 in peripheral blood mononuclear cells. Resveratrol was well-tolerated. CONCLUSIONS: Eight weeks administration of resveratrol did not significantly improve any features of NAFLD …
Resveratrol did not significantly alter transcription of NQO1, PTP1B, IL6, or HO1 in peripheral blood mononuclear cells. Resveratr …
Resveratrol metabolic fingerprinting after acute and chronic intakes of a functional beverage in humans.
Rotches-Ribalta M, Urpi-Sarda M, Martí MM, Reglero G, Andres-Lacueva C. Rotches-Ribalta M, et al. Electrophoresis. 2014 Jun;35(11):1637-43. doi: 10.1002/elps.201300262. Epub 2014 Jan 13. Electrophoresis. 2014. PMID: 24254301 Clinical Trial.
The study of the bioavailability of active compounds in functional foods, such as polyphenol-rich beverages, is required before making nutritional claims. In this work, we aimed to study the urinary excretion of resveratrol (RV), taking into consideration its gut and micro …
The study of the bioavailability of active compounds in functional foods, such as polyphenol-rich beverages, is required before making nutri …
Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life.
Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI. Militaru C, et al. Nutrition. 2013 Jan;29(1):178-83. doi: 10.1016/j.nut.2012.07.006. Epub 2012 Nov 13. Nutrition. 2013. PMID: 23153742 Free article. Clinical Trial.
This decrease was greater (39.7% at 60 d) for group 3 (calcium fructoborate), followed by group 2 (resveratrol plus calcium fructoborate, 30.3% at 60 d). The N-terminal prohormone of brain natriuretic peptide was significantly lowered by resveratrol (group 1, 59.7% …
This decrease was greater (39.7% at 60 d) for group 3 (calcium fructoborate), followed by group 2 (resveratrol plus calcium fructobor …
56 results